Finance, Markets

Celgene Corporation (NASDAQ:CELG) Signs Agreement With Beigene Ltd (ADR) (NASDAQ:BGNE) For Cancer Treatment

Celgene Corporation (NASDAQ:CELG) is planning to buy a share in Beigene Ltd (ADR) (NASDAQ:BGNE) to help in creating advance cancer immunotherapy treatment in China for tumor cancers. The deal will position the company in the medical field of immune-oncology.

If successful, Celgene could directly compete with both Merck and Bristol-Myers Squibb in producing the most novel cancer drugs for fighting cancer conditions. The drug works by blocking a particular interaction in the body that could prevent further immune response to cancer cells.

Based on the new agreement, Celgene will develop and commercialize a drug known as the BGB-A317 to take care of solid cancer tumors in various regions including US, Japan, entire Europe and other regions beyond Asia continent. Beigene will retain its rights to its original drug that treats blood cancers all over the world and for solid tumors within Asia.

Celgene already owns an immune-oncology that treats blood cancers through its acquisition of rights to the AstraZeneca’s product known as Imfinzi in blood tumors in 2015. The deal comes after the Food and Drug Administration (FDA) to hold three Merck’s Keytruda trials after a number of patients died. Celgene also teamed up in the trials. However, there are some doubts regarding how far Celgene is willing to commit to complete the development of BGB-A217.



Celgene needs to consider how gigantic the research and development is and undertaking it will require more immune-oncology resources to be deployed for probable combos. Several companies are working on a wide range of immune-oncology goals. But they will need to put more resources including IDO inhibitors such as the Incyte’s epanados tat and CTLA-4 inhibitor.

Celgene is paying $263 million upfront for the license fee and another $150 million as an equity investment to obtain the rights to create the drug called BGB-A317 for the treatment of solid tumors across the whole world.  The current deal will consolidate Celgene’s partnership with AstraZeneca Plc to produce durvalumabm to treat hematological malignancies and further increase the drug developer’s existence in Asia.

Previous ArticleNext Article

Related Post

Should You Buy CarMax Inc. (KMX) or Cars.com Inc. ... CarMax Inc. (NYSE:KMX) and Cars.com Inc. (NYSE:CARS) are the two most active stocks in the Auto Dealerships industry based on today’s trading volumes....
A Side-by-side Analysis of Hewlett Packard Enterpr... Hewlett Packard Enterprise Company (NYSE:HPE) shares are up more than 11.32% this year and recently increased 1.77% or $0.26 to settle at $14.97. HP I...
Whiting Petroleum Corporation (WLL): Don’t L... Whiting Petroleum Corporation (NYSE:WLL) gained 8.03% in yesterday’s session, going up from its prior closing price of $4.11 to $4.44, and has now rec...
How Does the Fundamental Picture Look for Advanced... Advanced Micro Devices, Inc. (NASDAQ:AMD) seems to be forming a pattern of major movements, providing only some crumbs of outlook for market participa...
Sirius XM Holdings Inc. (SIRI): Checking the Opera... Sirius XM Holdings Inc. (NASDAQ:SIRI)'s interesting series of developments are underway around the US stock market these days. Now trading with a mark...

Leave a Reply

Your email address will not be published. Required fields are marked *